MediCity tutkimuslaboratorio tarjoaa monipuolisen ja modernin ympäristön Turun yliopiston tutkimusryhmille. Työyhteisömme on kansainvälinen, sillä monet tutkijamme tulevat ulkomailta. Olemme osa monikulttuurista Biocity Turun yhteisöä (katso esittelyvideo).
MediCityssä toimii kliinisen, biolääketieteen,Turun Pet keskuksen ja InFLAMES lippulaivan tutkimusryhmiä (yhteensä noin 130 tutkijaa ja avustavaa henkilökuntaa). Tutkimusaiheet kattavat laajasti biolääketieteen tutkimuksen osa-alueita kuten immuunipuolustus, kuvantaminen, syöpätutkimus sekä tulehdustaudit. Tutkimusryhmät kuuluvat pääsääntöisesti lääketieteellisen tiedekunnan ja PET keskuksen tutkimusohjelmiin.
2024
Turun yliopiston ensimmäiset ImmuDocs-tohtorikoulutuspilotin projektit on valittu [8.4]
Valittujen joukossa:
Akira Takeda, MediCity, Unveiling macrophage subsets in metastatic lymph nodes and their impact on tumor immunity
Marko Salmi, MediCity, Lymphatic sinuses of draining lymph nodes
Alexander Mildner, MediCity/Institute of Biomedicine, Role of PPARg1 and PPARg2 in tissue-resident macrophage maintenance
Pieta Mattila, Institute of Biomedicine, Extracellular vesicles as novel regulators of the immune response and B lymphocyte activation
Sirpa Jalkanen, MediCity, Immune landscape in breast cancer – does it matter?
Maija Hollmén, Medicity, Dual-targeting of myeloid malignancies and their tumor microenvironment with bexmarilimab
ImmuDocs aikoo kouluttaa immunologia-alan osaajia [18.12.23, InFLAMES]
Elimistön syöjäsolujen tutkimisesta tuli Alexander Mildnerin intohimo [20.3]
2023
Uudesta lääkeaineesta löytyi uusi ominaisuus, esti koeoloissa okasolusyövän etenemistä [8.11]
Diana Lehotina voitti parhaan posterin palkinnon 49th Annual Meeting of the Scandinavian Society of Immunology seminaarissa [7.6]
Sakari Alhopuron säätiöltä apurahoja lääketieteen ja luonnontieteiden tutkijoille [30.5]
- Fair-Mäkelä Ruth, Turun yliopisto, InFLAMES-lippulaiva, MediCity, 60 000 € (jatkorahoitus), ”PLVAP-sensorin merkitys imusolmukkeen suodatustoiminnon säätelyssä”
Turun yliopistoon 11 uutta biotieteiden, terveyden ja ympäristön tutkimuksen akatemiahanketta [30.5]
- Tove Grönroos, PET-keskus, Translokaattoriproteiinin PET-kuvantaminen pään- ja kaulan alueen syövässä, 470 285 e
- Alexander Mildner, InFLAMES-lippulaiva: C/EBPß rooli CSF2-signaalissa hermotulehduksen aikana, 507 734 e
Dissertation defence (Medical Biochemistry and Genetics): MSc Marika Koivu [26.5]
- Dosentti Tove Grönroos ja työryhmä translokaattoriproteiinia pään ja kaulan alueen syövän sädehoidossa käsittelevään tutkimukseen, 14.000 e
Suomalaiseen Tiedeakatemiaan kuusi Turun yliopiston tutkijaa [9.5]
- Valittujen joukossa on MediCityn johtaja Marko Salmi
Väitös (lääketieteellinen mikrobiologia ja immunologia): FM Miro Viitala [14.4]
Uudet apurahat myönnetty – 24 miljoonaa euroa tukea lääketieteelle vuonna 2023 - Sigrid Juselius säätiön apurahoja Medicityssä työskenteleville tutkijoille:
- Klaus Elenius 65 000
- Pauliina Hartiala 45 000
- Kari Kurppa 50 000
- Alexander Mildner 60 000
- Miho Nakamura 45 000
- Cecilia Söderberg – Naucler 65 000 [27.3]
Sotaa paenneesta Diana Lehotinasta tuli Turussa tutkija – lääkärin työ saa odottaa [10.3]
- Diana työskentelee MediCityssä Sirpa Jalkasen ja Akira Takedan ryhmissä.
Arno Ylitalo voitti 3MT-kisan – edustaa Turun yliopistoa Coimbran kansainvälisessä kilpailussa [9.3]
”Ilman heitä en ikinä olisi tässä missä nyt olen” − Katso keitä akateemikko Sirpa Jalkanen kiittää huikeasta urastaan [Mediuutiset 4.3]
Lymfaturvotuksen hoitoon etsitään uusia keinoja [Lääkärilehti 28.2]
Väitös (lääketieteellinen mikrobiologia ja immunologia): MSc Dominik Eichin [29.1]
2022
Suomen Akatemialta yli 3,3 miljoonaa Turun yliopiston tutkimusinfrastruktuureille
- Sirpa Jalkanen, professori, tutkimusjohtaja, InFLAMES-lippulaiva: Turku Immunology Centre, 2 009 243 euroa [UTU 15.12]
Uusioimusolmukkeet auttavat immuunipuolustusta hyökkäämään syöpäsoluja vastaan [UTU 12.12]
Maija Hollmen won the second InFLAMES Idea Competition! As a prize she received a travelling grant worth 2000 euros. "The research idea has great potential for R2B funding and for collaborations within InFLAMES", the Innovation Service jury stated. [29.11.]
Syöpäsäätiö jakoi vuonna 2022 syöpätutkimukseen apurahoja ennätykselliset 7,35 miljoonaa euroa. Turun yliopiston tutkijoille apurahoja jaettiin yhteensä 680 000 euroa. Myös Medicityn tutkijoita oli saajien joukossa:
Ritva Pesosen testamenttisaannolla myönnetyt apurahat
professori Cecilia Söderberg-Nauclér (Turun yliopisto, Karolinska Institutet, InFLAMES-lippulaiva) ja tutkimusryhmä, 120 000 €, Prevention of radiation induced reactivation of. 2-vuotiseen tutkimustyöhön
Syöpäsäätiön käyttörahasto
akatemiatutkija, dosentti Maija Hollmén (Turun yliopisto, InFLAMES-lippulaiva) ja tutkimusryhmä, 140 000 €, Advancing macrophage-directed therapies in cancer. 2-vuotiseen tutkimustyöhön
[UTU 23.11]
”En haluaisi häiritä Diana, mutta näyttää siltä, että sota on alkanut” [Mediuutiset 16.5]
Väitös (kliiniset neurotieteet): FM Susanne Vainio [29.4]
Suomen Akatemia syyskuun 2021 haku, myönnetyt apurahat: [28.4]
- Ruth Fair-Mäkelä, Extracellular matrix-regulated mechanisms of immune responses in the lymph node, 289 631€
- Turun yliopistoon kaksi uutta akatemiatutkijaa ja seitsemän tutkijatohtoria biotieteiden, terveyden ja ympäristön tutkimukseen
Lääkäri ja akateemikko Sirpa Jalkaselle Suomalaisen Tiedeakatemian kunniapalkinto – ”Tässä uran vaiheessa tärkein roolini on tukea nuorempia tutkijoita” [mediuutiset 25.4]
Akateemikko Sirpa Jalkaselle Suomalaisen Tiedeakatemian vuoden 2022 kunniapalkinto [22.4]
Uusi tautimalli ilmentää MS-tulehdusta jo 16 tunnin kuluttua toimenpiteestä [Mediuutiset 22.4.]
Kokeellisia malleja voidaan soveltaa MS-taudin lääkkeiden ja radiolääkkeiden arvioinnissa [UTU 22.4]
Sigrid Juselius on myöntänyt Medicityssä työskenteleville tutkimusryhmille apurahoja [16.3]
Senior Group Leaders
- Salmi Marko, Turun yliopisto / Åbo universitet, 86 000, 2/3
- Jalkanen Sirpa, Turun yliopisto / Åbo universitet, 100 000, 2/3
- Hollmén Maija, Turun yliopisto / Åbo universitet, 64 000, 2/3
- Lempainen Johanna, Ilonen Jorma Turun yliopisto / Åbo universitet, 60 000, 1/2
- Zavialov Anton, Lamminmäki Urpo, Turun yliopisto / Åbo universitet, 69 000, 3/3
- Mattila Pieta, Turun yliopisto / Åbo universitet, 64 000, 3/3
Young Group Leaders
- Kurppa Kari, Turun yliopisto / Åbo universitet, 50 000 3/3
- Li Jianwei, Turun yliopisto / Åbo universitet, 45 000 2/2
- Takeda Akira, Turun yliopisto / Åbo universitet, 50 000 2/3
Väitös (patologia): MSc Alexey Sarapulov [11.3]
Turkuun perustettiin Kansallinen lääkekehityskeskus [UTU 4.2]
MediCity on vahvasti mukana InFLAMES lippulaivahankkeessa.
InFLAMES-lippulaiva (Immuunijärjestelmän innovaatiokeskus lääketieteen ja talouskasvun moottorina) on Turun yliopiston ja Åbo Akademin yhteinen hanke. Sen tavoite on olla kansainvälisesti tunnettu huipputason immunologisen tutkimuksen ja kehityksen keskus, joka on houkutteleva yhteistyökumppani kotimaisille ja kansainvälisille huippututkijoille ja yrityksille.
Tällä hetkellä meillä ei ole avoimia paikkoja.
MediCityn johtaja
Sihteeri
MediCityn Intranet (vaatii kirjautumisen)
Osoite
Turun yliopisto
Lääketieteellinen tiedekunta
MediCity Laboratorio
Biocity 4. krs
Tykistökatu 6A
20520 Turku
Seuraa meitä Twitterissä ja LinkedInissä
Tutkimusryhmät
Principal Investigator
Klaus Elenius
Professor of Medical Biochemistry,
Faculty of Medicine, University of Turku
MediCity Research Laboratories and Turku Center for Biotechnology
University of Turku and Åbo Akademi University
Cancer Research Laboratories, FICAN West
klaus.elenius [at] utu.fi
Description of Research
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
Current Topics
• Screens for predictive RTK mutations
• Novel RTK signaling mechanisms
• Development of preclinical models for development novel RTK inhibitors
• Sequencing of RTK inhibitor drug administration with cytotoxic agents
• In vitro “basket trials” with ErbB inhibitor drugs
• RTK signaling in angiogenesis and cardiovascular diseases
• RTKs in pediatric malignancies
• Biological role of novel ErbB4 isoforms in diseases and development
Principal Investigator
Senior Researcher, Turku PET Centre (University of Turku)
Adjunct Professor, Dept. Clinical Medicine (University of Turku)
tovgro [at] utu.fi
Description of Research
Our translational research focuses on evaluating and validating PET tracers for imaging the tumor microenvironment. We are especially interested in approaches for determining the level of radioresistance in solid tumors that affect radiotherapy treatment outcomes in cancer patients. Such tracers can be utilized for treatment planning and follow-up purposes in clinical settings. Another objective is to re-evaluate some existing tracers for their possible use as cancer imaging tools or to measure changes in cancer-dependent metabolism pathways on a whole-body level, which might affect treatment outcomes. We combine PET technology with state-of-the-art technologies for molecular biology utilizing cell lines, tumor models, and patient-derived samples.
Principal Investigator
Senior Research Fellow, Turku PET Centre, Docent, Institute of Biomedicine, Adj.prof.
merja.haaparanta-solin@utu.fi
+358 40 715 1742
Description of Research
My research interest is on validation and use of novel positron emission tomography (PET) radiopharmaceuticals (radiotracers) developed at Turku PET Centre. The main targets are receptors, transporters, abnormal proteins and neuroinflammation in the central nervous system.
In my research, I focus on investigating the pharmacokinetics of new PET tracers in healthy and animal disease models by utilizing noninvasive PET imaging techniques that provides a functional or metabolic assessment of normal tissue or disease conditions. This in vivo imaging is combined with computed tomography (CT) and with ex vivo digital autoradiography. An important part of my research is also the method development and analyses of radioactive metabolites of PET tracers during the time course of imaging."
Principal Investigator
MD, PhD, Senior Research Fellow, Medicity Research Laboratory
Docent, Plastic Surgeon, Department of Plastic and General Surgery, Turku University Hospital,
e-mail: pauliina.hartiala@utu.fi
Description of Research
Treatment of metastatic breast cancer requires surgical treatment and radiation therapy of the axillary lymph nodes. The disruption in the lymphatic flow may cause swelling of the affected limb known as lymphedema. Initial lymphedema often develops into chronic lymphedema, a progressive disease characterized by the loss of lymphatic function, accumulation of interstitial fluid and gradually to irreversible accumulation of fibrous adipose tissue. Lymphatic stasis, fibrosis, inflammation and adipose tissue expansion have been shown to play a role in lymphedema development, but the pathophysiology of lymphedema is still unresolved.
Our group investigates the pathophysiology, prediction and treatment of breast-cancer related lymphedema. The tissue composition and gene expression of normal and lymphedematous skin and adipose tissue with special emphasis on immune cells is investigated. We use single cell sequencing and mass cytometry (CyTOF) and imaging mass cytometry to obtain a comprehensive view on which cellular and molecular mediators are responsible for the initiation of adipose deposition in lymphedema. We are also characterizing the changes that take place in lymphatic endothelial cells in lymphatics as lymphedema progresses. The aim is to clarify the pathophysiology of lymphedema and to pave the way for novel therapeutic approaches for this chronic and debilitating condition.
Principal Investigator
Jyrki Heino
Scientific Director, BioCity Turku (BioCity Turku)
Professor, Biochemistry (Department of Biochemistry)
jyrki.heino [at] utu.fi
Description of Research
Our research group is studying the structure¬–function relationship of the collagen receptor integrins. The most important methods used include the production of recombinant protein domains, functional assays and mutations of the domains, bioinformatics as well as the expression and analysis of the full-length receptor proteins on cell surface. This has lead to a project aimed at development of small molecular inhibitors for collagen receptors.
In addition to the structural work we are also interested in integrin signaling, especially atypical signaling mechanisms, including low avidity integrin–ligand interaction and signaling by nonactivated integrins. Most recently, we have studied the role of collagen receptor signaling in prostate cancer and the consequences of post-translational modifications, such as citrullination, of the integrin ligands in inflammation In these experiments we use the general methods of molecular cell biology, imaging by confocal microscopy and proteomics. In a separate project we have developed new software for quantitative bioimaging (BioImageXD).
Group Members
Jarmo Käpylä, Senior Scientist, Ph.D., Docent
Pekka Rappu, Postdoctoral Researcher
Johanna Jokinen, Postdoctoral Researcher
Elina Siljamäki, Postdoctoral Researcher
Anna-Brita Puranen, Doctoral Candidates
Marjaana Ojalill, Doctoral Candidates
Salli Keinänen, Doctoral Candidates
Maria Tuominen, Laboratory Technician
Noora Virtanen, Undergraduate Student
Ville Jokinen, Undergraduate Student
Principal Investigator
PhD, Manager of Preclinical in vivo PET Imaging
Preclinical Imaging Unit, Turku PET Centre (University of Turku)
jatta.helin [at] utu.fi
Description of Research
The main goal of our research is to provide quantitative modeling tools that enable kinetic analyses of animal PET imaging data. Tracer kinetic models can be exploited to measure blood flow, membrane transport, metabolism, and ligand-receptor interactions noninvasively and quantitatively in various animal disease models tailored for metabolic disorders, and neurodegenerative and neuropsychiatric diseases. Ongoing projects aim at translating preclinically achieved data into human PET imaging protocols to be used in research and clinical settings.
Principal Investigator
Maija Hollmen
Academy Research Fellow, Department of Clinical Medicine (Department of Clinical Medicine),
Adjunct Professor, MediCity Research Laboratory (Faculty of Medicine)
maijal [at] utu.fi
Description of Research
Our research exploits a unique scavenger receptor Clever-1, expressed on a subpopulation of immunosuppressive macrophages, to alleviate tumor related inflammation and develop Clever-1 as a companion therapeutic, diagnostic, and prognostic biomarker to treat and identify patients under immunosuppression. This involves the use of in vivo tumor models and sophisticated immunological assays with cutting-edge technology and state-of-the-art imaging combined with fresh human cancer patient material to elucidate the function of Clever-1 in controlling macrophage mediated local and systemic immune responses. Our results potentially have a high impact in understanding the mechanism of macrophage-mediated immunosuppression in cancer and promoting anti-Clever-1 immunotherapy into clinical trials where it may have benefits in comparison with currently available immune activating drugs.
Principal Investigator
Sirpa Jalkanen
Professor, Academician
Institute of Biomedicine
sirpa.jalkanen [at] utu.fi
Description of Research
The overall goal of our research is to elucidate the mechanisms regulating the traffic of leukocytes and cancer cells in the body. Harmful leukocyte migration into the joints in rheumatoid arthritis and into the pancreas in diabetes are examples of diseases where leukocytes cause extensive destruction. These inflammatory diseases can be cured by inhibiting leukocyte trafficking. Also, metastasising malignant cells often use the same mechanisms as leukocytes when extravasating from blood to different organs or migrating via the lymphatics into distant sites. The results obtained can be utilized when new types of drugs are developed to treat harmful inflammations and cancer.
Principal Investigator
Jianwei Li
Senior Research Fellow, MediCity, PhD, Group Leader
jianwei.li [at] utu.fi
Description of Research
Molecular Systems Engineering is an emerging field by understanding the fundementals of molecular properties and dynamics in synthetic complex systems, and exploring sophisticated functions for advanced applications in biomedicine, materials and energy. Our laboratory uses the tools of dynamic combinatorial chemistry (DCC), supramolecular chemistry and computer chemistry to fabricate the framework of complex chemical systems, investigates the self-assembly in such systems and uncovers the working principles at molecular level behind them. We have learned that self-assembly can not only direct the formation of beautiful and intriguing structures i.e. catenanes and “Russian-doll”-like supramolecular architectures, but also promote the molecules to make copies of themselves as the living matters in nature. Currently we are trying to extend the board of DCC into the fields of materials science, enzymology and biology by three lines of research: 1) dynamic combinatorial biomaterials for controlling cell behaviors; 2) enzyme-directed DCC; and 3) DCC in vivo.
Principal Investigator
Adjunct Professor, Turku PET Centre
francisco.lopez [at] utu.fi
Description of Research
We work in the development and characterization of novel positron emission tomography (PET) radiotracers to investigate disease relevant targets for neurodegenerative, neuroinflammatory and neuropsychiatric diseases. We have special interest in engineering antibodies that are able to cross the blood brain barrier and use them as PET radiotracer to image brain targets (ImmunoPET approach). Furthermore, we used relevant disease models of neurodegeneration and neuroinflammation in conjunction with the PET radiotracers to investigate disease progression, and perform longitudinal pharmacological intervention studies.
Principal Investigator
Kari J. Kurppa, Senior Researcher, Institute of Biomedicine
kjkurp@utu.fi
Description of Research
Our aim is to understand the means cancer cells use to develop resistance to cancer therapies. Our special focus are the mechanisms that enable the establishment of minimal residual disease, or govern the maintenance of residual tumors following targeted cancer therapy. The overarching goal of our research is to develop rational combination strategies that will extend the long-term efficacy of clinically used cancer therapies.
While targeted therapy has transformed the treatment of cancer, the long-term efficacy of these strategies is hampered by acquired drug resistance. In many cases, clinical drug resistance is preceded by minimal residual disease (MRD) state, where residual tumors stay dormant for an extended period of time. Emerging evidence indicates that the establishment of MRD is mainly regulated by non-genetic mechanisms, as cancer cells adapt to treatment by acquiring new phenotypic states that no longer depend on the targeted oncogene. These slow-cycling drug tolerant cells can regain proliferative state upon drug withdrawal or acquisition of additional resistance mechanisms, and as such serve as a reservoir of dormant cells capable of re-initiating the growth of a drug resistant tumor. Understanding the mechanisms underlying the establishment or maintenance of minimal residual disease would enable the development of rational combination strategies aimed to prevent or limit residual disease, leading to prolonged survival of cancer patients.
Principal Investigator
InFLAMES Group Leader, Adjunct Professor, Institute of Biomedicine
pieta.mattila [at] utu.fi
Description of Research
We investigate the regulation of B lymphocyte activation that mounts specific and highly effective antibody responses against pathogens. However, if lymphocyte activation is defected, we face pathological conditions such as autoimmunity or lymphoma. In our research, we integrate advanced light microscopy and proteomic approaches with cellular and in vivo models, to gain novel understanding on the cell biological phenomena of B cell activation and immune responses.
Principal Investigator
Alexander Mildner, Associate Professor
alexander.mildner [at] utu.fi
Description of Research
Tissue resident macrophages are long-lived cells that are distributed throughout the body and migrate into the tissue during embryogenesis. They are specialized in ingesting and processing dead cells, debris and foreign materials, and in the recruitment of other immune cells – like monocytes – to sites of injury in response to inflammatory signals. Monocytes, on the other hand, represent short-lived cells that can be found in the peripheral circulation. Traditionally, it was assumed that monocytes represent an intermediate stage, linking mononuclear phagocyte precursors in the bone marrow with terminally differentiated tissue resident macrophages. However, this concept seems to hold true only for certain tissues. In most of the cases, embryo-derived tissue macrophages are endowed with an intrinsic self-renewal program to maintain homeostasis, while monocyte descendants are devoid of this capacity. Instead, monocytes are highly plastic cells and can differentiate – depending on the cellular context – into various cell types with fundamental different functions like effector monocytes, monocyte-derived dendritic cells and monocyte-derived macrophages.
The transcription factor C/EBPβ is expressed in cells of the myeloid lineage, especially in monocytes, macrophages and dendritic cells. Recently, we applied epigenetic approaches to identify C/EBPβ as one of the main regulators of monocyte and Alveolar macrophage development under physiological conditions. Deficiency of C/EBPβ in mice let to a complete absence of Ly6C- monocytes due to impaired induction of the monocytic survival factor Nr4a1. In Alveolar macrophages, C/EBPβ controlled the expression of a lipid catabolic program.
We are currently investigating the differentiation of myeloid cells under steady state as well as pathological conditions such as autoimmunity in various tissues using epigenetic approaches including ATACseq, ChIPseq and high resolution immune profiling like scRNA-Seq. The central goal of our laboratory is to identify new factors that are involved in the differentiation of monocytes and macrophages under pathological conditions. We hope to manipulate the fate and activation status of macrophages and thereby beneficially influence disease progression.
Current topics
Monocytes differentiation and function during neuroinflammation
Microglia heterogeneity
Tissue-specific function of macrophages
Group's website / Twitter @MildnerLab / Research Gate
Principal Investigator
Adjunct Professor, Department of Clinical Medicine, Senior Researcher at TCSM, Institute of Biomedicine
mihnak@utu.fi
Description of Research
Main goal of our research is to find a solution for bone diseases in elderly population, such as osteoarthritis and osteoporosis. Our research is aiming at multidisciplinary collaborations between medicine, cell biology and materials science.
My current research interest includes:
- Bio-inspired biomaterials to enhance bone regeneration through the manipulation of bone cells (osteoblasts, osteocytes and osteoclasts)
- New parameters for the evaluation of bone quality using knowledge of materials science
- Mechanism of osteolysis in aseptic loosening
- Engineering of bone to prevent osteoporosis
Keywords: Biomaterials, Tissue Engineering, Bone regeneration, Osteoblasts, Osteocytes, Osteoclasts, Osteolysis
Group members
Uruj Sarwar, Doctoral Candidate
Jorgan Sobrepena, Master Student
Leire Bergara Muguruza, Undergraduate Student
We are looking for students (undergraduates, masters, Ph.D. candidates all welcome)! Please feel free to contact/ visit us.
Selected Publications
Tuukkanen J, Nakamura M. Hydroxyapatite as a nanomaterial for tissue engineering and drug therapy. Curr Pharm Design, 2017: 23(26), 3786-3793.
Nakamura M, Hori N, Ando H, Namba S, Toyama T, Nishimiya N, Yamashita K. Surface Free Energy Predominates in Cell Adhesion to Hydroxyapatite through Wettability. Mater Sci Eng C 2016: 62, 283-292.
Nakamura M, Hiratai R, Hentunen T, Salonen J, Yamashita K. Hydroxyapatite with High Carbonate Substitutions Promotes Osteoclast Resorption through Osteocyte-like Cells. ACS Biomater Sci Eng 2016: 2 (2), 259-267.
Nakamura M, Hentunen T, Salonen J, Nagai A, Yamashita K. Characterization of bone mineral-resembling biomaterials for optimizing human osteoclast differentiation and resorption. J Biomed Mater Res A, 2013: 101A (11), 3141-3151.
Nakamura M, Soya T, Hiratai R, Nagai A, Hashimoto K, Morita I, Yamashita K. Endothelial cell migration and morphogenesis on silk fibroin scaffolds including hydroxyapatite electret. J Biomed Mater Res A 2012: 100A, 969-977.
Principal Investigator
Professor, InFLAMES Flagship
cecilia.naucler@utu.fi
Description of Research
The long-term goal of our projects is to further understand how cellular metabolism control immune activation, cancer cell growth, and the life cycle of human cytomegalovirus (HCMV) that appears to be closely involved in the pathogenesis of inflammatory disease and cancer. We hope that this will allow us to find new treatment strategies for many of our common diseases. Our research is carried out at Turku University, MediCity Research Laboratory and Karolinska Institutet.
HCMV is a common virus, infecting 70-90% of the worlds population. This virus is considered harmless for healthy individuals but may cause severe disease in immunocompromised patients. Emerging evidence also imply a role of this virus in inflammatory diseases and cancer. HCMV is reactivated by inflammation, can drive inflammatory processes and is often found in inflamed tissue specimens obtained from patients with inflammatory diseases such as SLE, rheumatoid arthritis, inflammatory bowel disease, cardiovascular diseases and aortic aneurysms, while rarely detected in healthy tissues. HCMV is also commonly found to be active in tumors of different origin such as glioblastoma, neuroblastoma, medulloblastoma, breast, colon, prostate and ovarian cancer. Both primary tumors as well as metastases are virus positive, while healthy tissues surrounding tumors and metastases are virus negative. We are currently studying the effect of anti-HCMV therapy in 220 glioblastoma patients in a randomized trial, VIGAS2. Retrospective analyses of so far treated patients (139 patients) indicate substantial prolonged survival time in patients receiving anti-viral therapy, which suggest a potential role of this virus in cancer.
Activation of immune cells depend on alterations in cellular metabolism; i.e the Warburg effect, which is also essential for cancer cells to grow. HCMV establishes the Warburg effect in infected cells, which appears to be essential for reactivation of latent HCMV and virus production Thereby our studies of viral regulation of cellular metabolism unifies the many diseases associated with HCMV. Although the metabolic alterations to the Warburg effect is essential for inflammation and cancer, it is not known how cells switch from normal metabolism to the Warburg effect. We have used HCMV as a tool to try to understand the underlying mechanisms of the Warburg effect in immune cells and cancer cells. We made unexpected insights into how cells with a normal metabolism switch to the Warburg effect, which allowed us to identify metabolic inhibitors that we are now testing how they affect immune cell activation and cancer cell growth.
Group Members
Hatem Abouguendia, Doctoral Researcher
Iqra Khawaja, Doctoral Student
Mohammad Pirouzfar, Doctoral Student
Päivi Ylä-Anttila
Shaghayegh Hasanpour, Doctoral Student
Principal Investigator
Vilhelmiina Parikka, MD, PhD
Senior Research Fellow, Paediatrics and Adolescent Medicine, Medicity Research Laboratory and Turku PET Centre
vilpar [at] utu.fi
Description of Research
The main interest of our research group is in pathophysiological mechanisms and treatment options for neonatal hypoxic-ischemic injury. The research project aims to provide deeper understanding of the pathological processes behind the brain injury, to identify tools for the early recognition of the injury and to develop new clinically relevant strategies for the treatment of this group of vulnerable infants. The research group has a special interest in the role of inflammation and endothelial injury in the pathophysiological process of the brain injury. The role of PET imaging scans as an early marker for metabolic changes and inflammation in a preclinical model of neonatal hypoxic-ischemic encephalopathy is actively studied.
Principal Investigator
Marko Salmi, MD, PhD
Professor of Molecular Medicine,
Medicity Research Laboratory and
Institute of Biomedicine
e-mail: marko.salmi@utu.fi
Tel: +358-50-3385678
Description of Research
Leukocyte migration from the blood and lymph into tissues is critical for generation of normal immune responses. Abnormal leukocyte traffic contributes to the pathogenesis of all inflammatory diseases and several other diseases, such as cancer. We study the molecular mechanisms and functional implications of leukocyte migration in the body. We have identified several new adhesion molecules (e.g. vascular adhesion protein-1 (VAP-1), CD73, stabilin-1, plasmalemma vesicle associated protein (Plvap)) on blood and lymphatic vessels and leukocytes, which mediate different steps of leukocyte extravasation from the vessels.
We have also studied the therapeutic value of modulating the function of these and other adhesion receptors in inflammation and cancer. We also elucidate the differentiation pathways of monocytes/macrophages by studying the role of the developmental origin and tissue niche for their plasticity and functions. In addition, we are interested in defining the routes by which antigens enter the lymph node parenchyma via the lymphatic vasculature during the triggering of immune responses. As a separate line of research, we have analyzed the value of adhesion molecules and cytokines as biomarkers of disease in population and patient cohorts.
Principal Investigator
Akira Takeda, PhD
Academy Research Fellow,
MediCity Research Laboratory,
InFLAMES flagship
e-mail: akitak@utu.fi
Tel. +358 29 450 4383
Description of Research
Although immune cells play a critical role in human diseases such as infection and cancer, structural cells including endothelial and stromal cells are also crucial for maintaining the function of the immune cells. Recent single-cell technologies showed multiple heterogenous subsets in structural cells that have not been considered before. The aim of our group is (1) to find unrecognized heterogeneous structural cell subsets in human organs including lymphoid organs and tumors using single-cell technologies, and (2) to find the new molecular mechanism between heterogeneous structural cells and immune cells in health and disease.
Principal Investigator
Associate Professor, Turku PET Centre (University of Turku and Turku University Hospital)
kianvi [at] utu.fi
Description of Research
The main focus of our research is to understand the function of human brown adipose tissue in health and in metabolic disorders. Current projects are focused on ascertaining the crosstalk between the gut microbiota/products and the immune system with brown adipose tissue function in humans.
This project functions under the framework of the INFLAMES flagship, funded by the Academy of Finland, and aims to: i) ascertain how the infiltrated immune cells within brown adipose tissue modulate its function, and ii) ascertain the mechanisms by which an inflammatory environment may induce brown adipose tissue dysfunction.
Principal Investigator
Anton Zavialov
Senior Research Fellow, Joint Biotechnology Laboratory (JBL)
anton.zavialov [at] utu.fi
Description of Research
We work in the field of structural biology and structure-based drug design. Our main methods are x-ray crystallography and cryo-electron microscopy. The main focus of our research is the unraveling of molecular mechanisms governing the interplay between microbial pathogens and their hosts, and the exploitation of these finding in medicine. We are particularly interested in host-pathogen interactions during the early steps of infection: bacterial attachment and biofilm formation mediated by fimbrial adhesins and host tissue invasion mediated by the Type III secretion system. Blocking these steps could prevent infections caused by antibiotic-resistant pathogens. Another line of our research explores the intricate cell signaling mechanism of the novel growth factor-enzyme, adenosine deaminase type 2 (ADA2). This study paves the way for the development of novel means to treat blood cancers and vascular disorders, including a genetic disease called deficiency of ADA2 (DADA2). In addition, we develop a novel ADA-based immuno-oncological therapy of advanced cancers.
Group Members
Minna Tuittila, Postdoctoral Researcher
Sari Paavilainen, Senior Researcher
Henri Malmi, Doctoral Candidate
Maksym Skaldin, Doctoral Candidate
Vladimir Zav’yalov, Visiting Professor
Selected publications
Skaldin M, Tuittila M, Zavialov And. V & Zavialov Ant. V (2018) Secreted bacterial adenosine deaminase is an evolutionary precursor of adenosine deaminase growth factor. Molecular Biology and Evolution, 35:2851-2861.
Pakharukova N, McKenna S, Tuittila M, Paavilainen S, Parilova O., Malmi H, Matthews S. & Zavialov AV (2018) Archaic and alternative chaperones preserve pilin folding energy by providing incomplete structural information. Journal of Biological Chemistry, 293(44):17070-17080.
Pakharukova N, Tuittila M, Paavilainen S, Malmi H, Parilova O, Teneberg S, Knight S & Zavialov AV‡ (2018) Structural basis for Acinetobacter baumannii biofilm formation. Proc Natl Acad Sci U S A 115, 5558-5563
Gurung J, Amer A, Francis MK, Costa TRD, Chen S, Zavialov AV & Francis MS (2018) Heterologous Complementation Studies With the YscX and YscY Protein Families Reveals a Specificity for Yersinia pseudotuberculosis Type III Secretion. Frontiers in cellular and infection microbiology 8, 80.
Pakharukova N, Roy SP, Tuttila MT, Paavilanen S, Ingars A-K, Skaldin M, Lamminmäki U, Härt T, Teneberg S. & Zavialov AV (2016). Structural basis for Myf and Psa fimbriae-mediated tropism of pathogenic strains of Yersinia for host tissues. Molecular Microbiology, 102, 593–610.
Pakharukova N., Garnett G, Tuittila MT, Paavilainen S., Diallo M, Xu Y., Matthews S. and Zavialov AV (2015) Structural insight into archaic and alternative chaperone-usher pathways reveals non-classical mechanism of pilus biogenesis. PLoS Pathogens, 11:e1005269.
Amer A, Gurung J, Costa T, Zavialov AV, Forsberg Å & Francis M (2015) YopN and TyeA hydrophobic contacts required for regulating Ysc-Yop type III secretion activity by Yersinia pseudotuberculosis. Frontiers in cellular and infection microbiology, 6:66.
Berry A, Yang Y, Pakharukova N, Garnett J, Lee W, Cota E, Marchant J, Roy S, Tuittila M, Liu B, Inman K, Ruiz-Perez F, Mandomando I, Nataro J, Zavialov AV and Matthews S (2014) Structural insight into host recognition by aggregative adherence fimbriae of enteroaggregative Escherichia coli. PLoS Pathogens, 10, e1004404
Ryhmänjohtajat
Viimeisimmät julkaisut
Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments (2024)
Evaluation of PET imaging as a tool for detecting neonatal hypoxic-ischemic encephalopathy in a preclinical animal model (2024)
Anchoring Cu2O nanoparticles on g-C3N4 nanosheets for enhanced photocatalytic performance (2024)
Macrophage mannose receptor CD206 targeting of fluoride‐18 labeled mannosylated dextran: A validation study in mice (2024)
Seuraa meitä Twitterissä
Sinua voisi kiinnostaa myös
Johanna Ivaskalle ja Lauri Nummenmaalle 2,5 miljoonan euron EU-rahoitukset syöpätutkimukseen ja kielteisten tunteiden tutkimiseen
